Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.